文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

住院期间二甲双胍使用与2型糖尿病合并脓毒症危重成人患者死亡率的关联

Association of Metformin Use During Hospitalization and Mortality in Critically Ill Adults With Type 2 Diabetes Mellitus and Sepsis.
PubMed 文献 · Crit Care Med · 2022-02-07
一句话结论回顾性队列研究显示,2型糖尿病合并脓毒症的ICU患者住院期间使用二甲双胍与90天死亡率降低相关(OR 0.46)。

该回顾性队列研究纳入2008年10月至2014年12月宾夕法尼亚州16家医院ICU收治的14,847例2型糖尿病合并脓毒症成人患者,比较住院期间使用与未使用二甲双胍者的90天死亡率。682例(4.6%)使用二甲双胍,14,165例(95.4%)未使用。在1:4倾向性评分匹配的2,691例患者中,二甲双胍暴露(n=599)与90天死亡率降低相关(11.9% vs 22.7%;OR 0.46;95%CI 0.35-0.60),并与严重急性肾损伤减少(50% vs 57%;OR 0.75;95%CI 0.62-0.90)、1年主要不良肾脏事件减少(OR 0.27;95%CI 0.22-0.68)及肾脏恢复增加(95% vs 86%;OR 6.43;95%CI 3.42-12.1)相关。作者结论认为住院期间二甲双胍暴露与2型糖尿病合并脓毒症患者90天死亡率降低相关。

要点

  • 在倾向性评分匹配的2,691例2型糖尿病合并脓毒症ICU患者中,住院期间使用二甲双胍与90天死亡率降低相关(11.9% vs 22.7%;OR 0.46;95%CI 0.35-0.60)。
  • 二甲双胍暴露与严重急性肾损伤减少相关(50% vs 57%;OR 0.75;95%CI 0.62-0.90)。
  • 二甲双胍暴露与1年主要不良肾脏事件减少相关(OR 0.27;95%CI 0.22-0.68)。
  • 二甲双胍暴露与肾脏恢复增加相关(95% vs 86%;OR 6.43;95%CI 3.42-12.1)。
  • 总体14,847例患者中仅682例(4.6%)住院期间使用二甲双胍,14,165例(95.4%)未使用。

适用人群与场景

  • 2008年10月至2014年12月宾夕法尼亚州16家医院ICU收治的成人2型糖尿病合并脓毒症患者。

研究设计与关键结果

  • 回顾性队列研究,纳入16家医院ICU的14,847例2型糖尿病合并脓毒症成人患者,其中682例(4.6%)住院期间使用二甲双胍,14,165例(95.4%)未使用。
  • 经1:4倾向性评分匹配后共2,691例,二甲双胍暴露组599例,90天死亡率11.9%(71/599) vs 未暴露组22.7%(475/2,092),OR 0.46(95%CI 0.35-0.60)。
  • 严重急性肾损伤发生率:二甲双胍暴露组50% vs 未暴露组57%,OR 0.75(95%CI 0.62-0.90)。
  • 1年主要不良肾脏事件:OR 0.27(95%CI 0.22-0.68)。
  • 肾脏恢复率:二甲双胍暴露组95% vs 未暴露组86%,OR 6.43(95%CI 3.42-12.1)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为住院期间二甲双胍暴露与2型糖尿病合并脓毒症患者90天死亡率降低相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Whether metformin exposure is associated with improved outcomes in patients with type 2 diabetes mellitus and sepsis.

DESIGN: Retrospective cohort study.

SETTING: Patients admitted to ICUs in 16 hospitals in Pennsylvania from October 2008 to December 2014.

PATIENTS: Adult critical ill patients with type 2 diabetes mellitus and sepsis.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: We conducted a retrospective cohort study to compare 90-day mortality in diabetic patients with sepsis with and without exposure to metformin during hospitalization. Data were obtained from the electronic health record of a large healthcare system in Pennsylvania from October 2008 to December 2014, on patients admitted to the ICU at any of the 16 hospitals within the system. The primary outcome was mortality at 90 days. The absolute and adjusted odds ratio (OR) with 95% CI were calculated in a propensity score-matched cohort. Among 14,847 patients with type 2 diabetes mellitus and sepsis, 682 patients (4.6%) were exposed to metformin during hospitalization and 14,165 (95.4%) were not. Within a total of 2,691 patients subjected to propensity score-matching at a 1:4 ratio, exposure to metformin (n = 599) was associated with decreased 90-day mortality (71/599, 11.9% vs 475/2,092, 22.7%; OR, 0.46; 95% CI, 0.35-0.60), reduced severe acute kidney injury (50% vs 57%; OR, 0.75; 95% CI, 0.62-0.90), less Major Adverse Kidney Events at 1 year (OR, 0.27; 95% CI, 0.22-0.68), and increased renal recovery (95% vs 86%; OR, 6.43; 95% CI, 3.42-12.1).

CONCLUSIONS: Metformin exposure during hospitalization is associated with a decrease in 90-day mortality in patients with type 2 diabetes mellitus and sepsis.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Gómez H, Del Rio-Pertuz G, Priyanka P, et al. Association of Metformin Use During Hospitalization and Mortality in Critically Ill Adults With Type 2 Diabetes Mellitus and Sepsis. Crit Care Med. 2022. PMID: 35120041. doi:10.1097/CCM.0000000000005468

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。